A fireside chat with a leading KOL involved in cancer research on resistance.
A look a one company's approach to DDR and potential combination opportunities in this niche
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts
With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
BSB Reader Mailbag on TRK/ROS1/ALK inhibitors
An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition
Through the keyhole with a look at AZN and MedImmune's IO portfolio
Encouraging new developments in GBM with a novel CAR T cell therapy
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.
Five emerging cancer research trends we picked up at AACR17 that you should be aware of.
Interview with Professor Peter Schmid, Barts Cancer Institute.
Commentary on Tuesday at 2017 AACR annual meeting in Washington DC.
Commentary on Monday at the 2017 AACR annual meeting.
Commentary on Sunday at the 2017 AACR annual meeting
Highlights from Day 1 at AACR17
A look at some of the key sessions featuring checkpoint blockade at the AACR 2017 annual meeting
A comprehensive review of the key abstracts in the CAR T cell therapy niche and hints of the latest emerging trends
A look at how research into transcription factors, super enhancers, chromatin regulation and broom/chromodomains is changing the way we look at cancer
With increasing competition in the CDK4/6 space in HR+ HER2- metastatic breast cancer, how are things shaping up?
A look at a new area of immune-oncology that looks set to be in the consciousness more over the next few years
PARP! PARP! What's hot in ovarian cancer at SGO and AACR?
Overcoming immune suppression in the tumour microenvironment
Washington Monument After exploring a mechanistic approach and a tumour type as part of our AACR annual…
A look at some recent clinical data and what we can learn from the new data expected at AACR in DC
The first of our strategic and thematic AACR Previews for the 2017 annual meeting is here